Stem cell therapies in the clinic

被引：1

作者：

Acharya, Shrinivas ^{[1
,2
]}

Shaha, Suyog ^{[1
,2
]}

Bibbey, Michael Griffith ^{[1
,2
]}

Mukherji, Malini ^{[1
,2
]}

Zhao, Zongmin ^{[3
]}

Mitragotri, Samir ^{[1
,2
]}

机构：

[1] Harvard Univ, John A Paulson Sch Engn & Appl Sci, Allston, MA 02138 USA

[2] Harvard Univ, Wyss Inst Biolog Inspired Engn, Boston, MA 02115 USA

[3] Univ Illinois, Coll Pharm, Dept Pharmaceut Sci, Chicago, IL 60607 USA

来源：

BIOENGINEERING & TRANSLATIONAL MEDICINE | 2025年

基金：

美国国家卫生研究院; 美国国家科学基金会;

关键词：

cell; cell therapy; clinical translation; clinical trials; HSC; iPSC; MSC; stem cell; PROOF-OF-CONCEPT; BONE-MARROW; STROMAL CELLS; DIABETES-MELLITUS; TRANSPLANTATION; EFFICACY; PROGRESS; SAFETY; DONOR; OSTEOARTHRITIS;

D O I：

10.1002/btm2.70000

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Stem cell therapies have emerged as a transformative approach in modern medicine, with the potential to address and possibly cure a broad spectrum of diseases. These therapies utilize living stem cells that can perform complex biological functions not replicable by traditional drugs. Stem cell therapies have an expanding therapeutic landscape, with several products already approved and numerous clinical trials underway. Among the various stem cell types, hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) are most widely studied. In this review, we provide a detailed analysis of the current clinical landscape of stem cell therapies. We review 27 stem cell products that have received regulatory approvals and discuss 800 ongoing clinical trials, with a focus on HSCs and MSCs. We also discuss the critical challenges to be addressed to facilitate the clinical translation of stem cell therapies.

引用

页数：25

共 50 条

[31] Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016?
Barker, Roger A.
Parmar, Malin
Kirkeby, Agnete
Bjorklund, Anders
Thompson, Lachlan
Brundin, Patrik
[J]. JOURNAL OF PARKINSONS DISEASE, 2016, 6 (01) : 57 - 63
[32] Efficacy and safety of mesenchymal stem cell therapies for ischemic stroke: a systematic review and meta-analysis
Shen, Zhiyuan
Tang, Xian
Zhang, Yaxin
Jia, Yicun
Guo, Xin
Guo, Xiaosu
Bao, Junqiang
Xie, Xiongwei
Xing, Yuan
Xing, Jun
Tian, Shujuan
[J]. STEM CELLS TRANSLATIONAL MEDICINE, 2024, 13 (09) : 886 - 897
[33] Stem Cell-Induced Cell Motility: A Removable Obstacle on the Way to Safe Therapies?
Rosner, Margit
Hengstschlager, Markus
[J]. STEM CELLS TRANSLATIONAL MEDICINE, 2022, 11 (01) : 26 - 34
[34] Comparing atmospheric and hypoxic cultured mesenchymal stem cell transcriptome: implication for stem cell therapies targeting intervertebral discs
Elabd, C.
Ichim, T. E.
Miller, K.
Anneling, A.
Grinstein, V.
Vargas, V.
Silva, F. J.
[J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2018, 16
[35] Is Stem Cell Commerce in Small Animal Therapies Scientifically and Morally Justified?
Pinheiro, Luane Lopes
de Lima, Ana Rita
Branco, Erika
[J]. STEM CELL REVIEWS AND REPORTS, 2019, 15 (04) : 506 - 518
[36] Editorial: Safety, Efficacy and Mechanisms of Action of Mesenchymal Stem Cell Therapies
Moll, Guido
Hoogduijn, Martin J.
Ankrum, James A.
[J]. FRONTIERS IN IMMUNOLOGY, 2020, 11
[37] Mesenchymal stem cell therapies for Alzheimer's disease: preclinical studies
Zhao, Xiaorong
Li, Dandan
Zhang, Li
Niu, Yuhu
Wang, Wenzhuo
Niu, Bo
[J]. METABOLIC BRAIN DISEASE, 2021, 36 (07) : 1687 - 1695
[38] Enabling stem cell therapies for tissue repair: Current and future challenges
Wong, Victor W.
Sorkin, Michael
Gurtner, Geoffrey C.
[J]. BIOTECHNOLOGY ADVANCES, 2013, 31 (05) : 744 - 751
[39] Cell-based Therapies: Current Issues and Future Directions
Stewart, Matthew C.
[J]. VETERINARY CLINICS OF NORTH AMERICA-EQUINE PRACTICE, 2011, 27 (02) : 393 - +
[40] Recent advances of biomaterials in stem cell therapies
Xue, Yonger
Baig, Rafia
Dong, Yizhou
[J]. NANOTECHNOLOGY, 2022, 33 (13)

← 1 2 3 4 5 →